Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression
Filip Liebsch(TH Köln - University of Applied Sciences), Gerhard Multhaup(McGill University), Philip Scheltens(Amsterdam University Medical Centers), Luka Kulic(University of Zurich), Judes Poirier(Douglas Mental Health University Institute), Wiesje M. van der Flier(Amsterdam Neuroscience), Paul Säftig(Christian-Albrechts-Universität zu Kiel), Adeola Shobo(McGill University), Vivienne Engelschalt(Freie Universität Berlin), Peter Kunach(Southwestern Medical Center), Irem Ulku(McGill University), John C.S. Breitner(Alzheimer’s Disease Neuroimaging Initiative), Charlotte E. Teunissen(Amsterdam Neuroscience), Pedro Rosa‐Neto(Center for Diagnosis and Research on Alzheimer's Disease), Mark A. Hancock(McGill University), Christoph Höck(Inserm), Randall J. Bateman(Washington University in St. Louis)
Cited by 62
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k